Format

Send to

Choose Destination
Expert Rev Endocrinol Metab. 2016 Jan 2;11(1):7-19. Epub 2015 Nov 18.

Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes.

Author information

1
Oxford Centre for Diabetes Endocrinology and Metabolism, NIHR Oxford Biomedical Research Centre, Churchill Hospital , Headington, Oxford , UK.
2
Endocrinology, Aurora Advanced Healthcare , Milwaukee , WI , USA.
3
Department of Endocrinology and Metabolism, University of Manitoba , Winnipeg , MB , Canada.

Abstract

The progressive nature of type 2 diabetes necessitates that treatment is intensified as the disease advances. Several studies have shown that basal insulin and glucagon-like peptide-1 receptor agonists (GLP-1RAs) can be used in combination to successfully improve glycemic control and this combination is increasingly being considered as an alternative to intensification with prandial insulin. Insulin degludec/liraglutide (IDegLira) is the first fixed-ratio combination of a basal insulin and a GLP-1RA in a single formulation. Here we consider the benefits and potential limitations of such a combination, focusing on the unique modes of action of insulin degludec and the once-daily GLP-1RA liraglutide. IDegLira offers an efficacious combination therapy (mean end-of-trial HbA1c was 6.4-6.9% across the five completed Phase 3 trials), which was well-tolerated in clinical trials. The complementary modes of action resulted in a low rate of hypoglycemia and no weight gain in insulin-treated patients. As a once-daily injection with effects on both fasting and post prandial hyperglycemia, IDegLira has the potential to help many patients reach glycemic target (60-81% of patients achieved HbA1c <7% in clinical trials).

KEYWORDS:

IDegLira; glucagon-like peptide-1 receptor agonist; insulin; type 2 diabetes

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center